REPL analyst estimates
Replimune (REPL) analyst ratings, the average price target and its range, and every firm's latest call.
REPL analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 29, 2026 | Leerink Partners | Replimune price target raised to $31 from $19 at Leerink | $31.00 |
| Oct 28, 2026 | Jefferies | Replimune price target raised to $29 from $24 at Jefferies | $29.00 |
| Aug 7, 2026 | Wedbush | Wedbush Upgrades Replimune Group (REPL) to Outperform | $19.00 |
| Aug 7, 2026 | BMO Capital | Replimune price target raised to $20 from $16 at BMO Capital | $20.00 |
| Aug 4, 2026 | Leerink Partners | Leerink Upgrades Replimune Group (REPL) to Outperform | $17.00 |
| Jul 31, 2026 | Wedbush | Wedbush Upgrades Replimune Group (REPL) to Outperform | $12.00 |
| Jun 30, 2026 | BMO Capital | Replimune upgraded to Outperform from Market Perform at BMO Capital | $16.00 |
| Jun 30, 2026 | Wedbush | Replimune price target raised to $9 from $6 at Wedbush | $9.00 |
| Feb 5, 2026 | Piper Sandler | Replimune price target raised to $14 from $13 at Piper Sandler | $14.00 |
| Nov 3, 2025 | BMO Capital | Replimune upgraded to Market Perform from Underperform at BMO Capital | $11.00 |
| Oct 27, 2025 | H.C. Wainwright | Replimune upgraded to Buy from Neutral at H.C. Wainwright | $12.00 |
| Oct 20, 2025 | Wedbush | Wedbush upgrades Replimune to Outperform amid second BLA review | $18.00 |
| Jan 22, 2025 | BMO Capital | Replimune price target raised to $27 from $18 at BMO Capital | $27.00 |
| Dec 3, 2024 | Jefferies | Replimune Group (REPL) PT Raised to $19 at Jefferies | $19.00 |
| Jun 7, 2024 | H.C. Wainwright | Replimune Group price target raised to $17 from $12 at H.C. Wainwright | $17.00 |
- 8 firms rate REPL: 5 buy, 2 hold, 1 sell.
- The average price target is $24.75 from 4 analysts, from $19.00 to $31.00.
Updated 2026-11-02 23:10 UTC